-
Je něco špatně v tomto záznamu ?
Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies
RWM. Pauwels, CJ. van der Woude, D. Nieboer, EW. Steyerberg, MJ. Casanova, JP. Gisbert, NA. Kennedy, CW. Lees, E. Louis, T. Molnár, K. Szántó, E. Leo, S. Bots, R. Downey, M. Lukas, WC. Lin, A. Amiot, C. Lu, X. Roblin, K. Farkas, JB. Seidelin, M....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, metaanalýza, přehledy, práce podpořená grantem
Grantová podpora
MR/S034919/1
Medical Research Council - United Kingdom
- MeSH
- adalimumab terapeutické užití MeSH
- Crohnova nemoc * farmakoterapie MeSH
- imunosupresiva terapeutické užití MeSH
- infliximab terapeutické užití MeSH
- inhibitory TNF * terapeutické užití MeSH
- lidé MeSH
- nekróza MeSH
- recidiva MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
BACKGROUND & AIMS: Tools for stratification of relapse risk of Crohn's disease (CD) after anti-tumor necrosis factor (TNF) therapy cessation are needed. We aimed to validate a previously developed prediction model from the diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressants (STORI) trial, and to develop an updated model. METHODS: Cohort studies were selected that reported on anti-TNF cessation in 30 or more CD patients in remission. Individual participant data were requested for luminal CD patients and anti-TNF treatment duration of 6 months or longer. The discriminative ability (concordance-statistic [C-statistic]) and calibration (agreement between observed and predicted risks) were explored for the STORI model. Next, an updated prognostic model was constructed, with performance assessment by cross-validation. RESULTS: This individual participant data meta-analysis included 1317 patients from 14 studies in 11 countries. Relapses after anti-TNF cessation occurred in 632 of 1317 patients after a median of 13 months. The pooled 1-year relapse rate was 38%. The STORI prediction model showed poor discriminative ability (C-statistic, 0.51). The updated model reached a moderate discriminative ability (C-statistic, 0.59), and included clinical symptoms at cessation (hazard ratio [HR], 2.2; 95% CI, 1.2-4), younger age at diagnosis (HR, 1.5 for A1 (age at diagnosis ≤16 years) vs A2 (age at diagnosis 17 - 40 years); 95% CI, 1.11-1.89), no concomitant immunosuppressants (HR, 1.4; 95% CI, 1.18-172), smoking (HR, 1.4; 95% CI, 1.15-1.67), second line anti-TNF (HR, 1.3; 95% CI, 1.01-1.69), upper gastrointestinal tract involvement (HR, 1.3 for L4 vs non-L4; 95% CI, 0.96-1.79), adalimumab (HR, 1.22 vs infliximab; 95% CI, 0.99-1.50), age at cessation (HR, 1.2 per 10 years younger; 95% CI, 1-1.33), C-reactive protein (HR, 1.04 per doubling; 95% CI, 1.00-1.08), and longer disease duration (HR, 1.07 per 5 years; 95% CI, 0.98-1.17). In subanalysis, the discriminative ability of the model improved by adding fecal calprotectin (C-statistic, 0.63). CONCLUSIONS: This updated prediction model showed a reasonable discriminative ability, exceeding the performance of a previously published model. It might be useful to guide clinical decisions on anti-TNF therapy cessation in CD patients after further validation.
1st Department of Medicine University of Szeged Szeged Hungary
Department of Biomedical Data Sciences Leiden University Medical Center Leiden The Netherlands
Department of Digestive Diseases Hospital Universitario Virgen del Rocío Seville Spain
Department of Gastro Enterology INSERM CIC 1408 Paris France
Department of Gastroenterology and Hepatology Western General Hospital Edinburgh United Kingdom
Department of Gastroenterology Herlev Hospital Herlev Denmark
Department of Public Health Erasmus University Medical Center Rotterdam The Netherlands
Division of Gastroenterology Calgary Alberta Canada
Division of Gastroenterology Zeidler Ledcor Center University of Alberta Edmonton Alberta Canada
Exeter Inflammatory Bowel Disease Research Group University of Exeter Exeter United Kingdom
Inflammatory Bowel Disease Clinical and Research Centre Iscare a s Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024987
- 003
- CZ-PrNML
- 005
- 20221031100808.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cgh.2021.03.037 $2 doi
- 035 __
- $a (PubMed)33933376
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pauwels, Renske W M $u Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
- 245 10
- $a Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies / $c RWM. Pauwels, CJ. van der Woude, D. Nieboer, EW. Steyerberg, MJ. Casanova, JP. Gisbert, NA. Kennedy, CW. Lees, E. Louis, T. Molnár, K. Szántó, E. Leo, S. Bots, R. Downey, M. Lukas, WC. Lin, A. Amiot, C. Lu, X. Roblin, K. Farkas, JB. Seidelin, M. Duijvestein, GR. D'Haens, AC. de Vries, CEASE Study Group
- 520 9_
- $a BACKGROUND & AIMS: Tools for stratification of relapse risk of Crohn's disease (CD) after anti-tumor necrosis factor (TNF) therapy cessation are needed. We aimed to validate a previously developed prediction model from the diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressants (STORI) trial, and to develop an updated model. METHODS: Cohort studies were selected that reported on anti-TNF cessation in 30 or more CD patients in remission. Individual participant data were requested for luminal CD patients and anti-TNF treatment duration of 6 months or longer. The discriminative ability (concordance-statistic [C-statistic]) and calibration (agreement between observed and predicted risks) were explored for the STORI model. Next, an updated prognostic model was constructed, with performance assessment by cross-validation. RESULTS: This individual participant data meta-analysis included 1317 patients from 14 studies in 11 countries. Relapses after anti-TNF cessation occurred in 632 of 1317 patients after a median of 13 months. The pooled 1-year relapse rate was 38%. The STORI prediction model showed poor discriminative ability (C-statistic, 0.51). The updated model reached a moderate discriminative ability (C-statistic, 0.59), and included clinical symptoms at cessation (hazard ratio [HR], 2.2; 95% CI, 1.2-4), younger age at diagnosis (HR, 1.5 for A1 (age at diagnosis ≤16 years) vs A2 (age at diagnosis 17 - 40 years); 95% CI, 1.11-1.89), no concomitant immunosuppressants (HR, 1.4; 95% CI, 1.18-172), smoking (HR, 1.4; 95% CI, 1.15-1.67), second line anti-TNF (HR, 1.3; 95% CI, 1.01-1.69), upper gastrointestinal tract involvement (HR, 1.3 for L4 vs non-L4; 95% CI, 0.96-1.79), adalimumab (HR, 1.22 vs infliximab; 95% CI, 0.99-1.50), age at cessation (HR, 1.2 per 10 years younger; 95% CI, 1-1.33), C-reactive protein (HR, 1.04 per doubling; 95% CI, 1.00-1.08), and longer disease duration (HR, 1.07 per 5 years; 95% CI, 0.98-1.17). In subanalysis, the discriminative ability of the model improved by adding fecal calprotectin (C-statistic, 0.63). CONCLUSIONS: This updated prediction model showed a reasonable discriminative ability, exceeding the performance of a previously published model. It might be useful to guide clinical decisions on anti-TNF therapy cessation in CD patients after further validation.
- 650 _2
- $a adalimumab $x terapeutické užití $7 D000068879
- 650 12
- $a Crohnova nemoc $x farmakoterapie $7 D003424
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a infliximab $x terapeutické užití $7 D000069285
- 650 _2
- $a nekróza $7 D009336
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a inhibitory TNF $x terapeutické užití $7 D000079424
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a van der Woude, C Janneke $u Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Nieboer, Daan $u Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Steyerberg, Ewout W $u Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Casanova, María J $u Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
- 700 1_
- $a Gisbert, Javier P $u Department of Gastroenterology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Madrid, Spain
- 700 1_
- $a Kennedy, Nick A $u Exeter Inflammatory Bowel Disease Research Group, University of Exeter, Exeter, United Kingdom; Department of Gastroenterology and Hepatology, Western General Hospital, Edinburgh, United Kingdom
- 700 1_
- $a Lees, Charlie W $u Department of Gastroenterology and Hepatology, Western General Hospital, Edinburgh, United Kingdom
- 700 1_
- $a Louis, Edouard $u Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire de Liège, Liège, Belgium
- 700 1_
- $a Molnár, Tamás $u First Department of Medicine, University of Szeged, Szeged, Hungary
- 700 1_
- $a Szántó, Kata $u First Department of Medicine, University of Szeged, Szeged, Hungary
- 700 1_
- $a Leo, Eduardo $u Department of Digestive Diseases, Hospital Universitario Virgen del Rocío, Seville, Spain
- 700 1_
- $a Bots, Steven $u Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Academic Medical Centre, Amsterdam, The Netherlands
- 700 1_
- $a Downey, Robert $u Department of Gastroenterology and Hepatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, National Health Service Foundation Trust, Sheffield, United Kingdom
- 700 1_
- $a Lukas, Milan $u Inflammatory Bowel Disease Clinical and Research Centre, Iscare a.s, Prague, Czech Republic; Institute of Medical Biochemistry and Laboratory Diagnostics, First Medical Faculty, General Teaching Hospital, Prague, Czech Republic
- 700 1_
- $a Lin, Wei C $u Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
- 700 1_
- $a Amiot, Aurelien $u Department of Gastroenterology, Assistance Publique-Hôpitaux de Paris, Paris Est Creteil University, Henri Mondor Hospital, Paris Est Creteil University; Department of Gastroenterology, Paris Est-Créteil Val de Marne University, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Creteil, France
- 700 1_
- $a Lu, Cathy $u Division of Gastroenterology, Zeidler Ledcor Center, University of Alberta, Edmonton, Alberta, Canada; Division of Gastroenterology, Calgary, Alberta, Canada
- 700 1_
- $a Roblin, Xavier $u Department of Gastro-Enterology, INSERM CIC 1408, Paris, France; Department of Gastroenterology, University of Saint Etienne, Centre Hospitalier Universitaire Hopital Nord, Saint Etienne, France
- 700 1_
- $a Farkas, Klaudia $u First Department of Medicine, University of Szeged, Szeged, Hungary
- 700 1_
- $a Seidelin, Jakob B $u Department of Gastroenterology, Herlev Hospital, Herlev, Denmark
- 700 1_
- $a Duijvestein, Marjolijn $u Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a D'Haens, Geert R $u Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a de Vries, Annemarie C $u Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: a.c.devries@erasmusmc.nl
- 710 2_
- $a CEASE Study Group
- 773 0_
- $w MED00182421 $t Clinical gastroenterology and hepatology $x 1542-7714 $g Roč. 20, č. 8 (2022), s. 1671-1686.e16
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33933376 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100806 $b ABA008
- 999 __
- $a ok $b bmc $g 1854602 $s 1176277
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 20 $c 8 $d 1671-1686.e16 $e 20210430 $i 1542-7714 $m Clinical gastroenterology and hepatology $n Clin Gastroenterol Hepatol $x MED00182421
- GRA __
- $a MR/S034919/1 $p Medical Research Council $2 United Kingdom
- LZP __
- $a Pubmed-20221017
